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In the central nervous system (CNS), the transcription factor nuclear factor (NF)-
 
 
 
B is a key 
regulator of inflammation and secondary injury processes. After trauma or disease, the 
expression of NF-
 
 
 
B–dependent genes is highly activated, leading to both protective and 
detrimental effects on CNS recovery. We demonstrate that selective inactivation of 
astroglial NF-
 
 
 
B in transgenic mice expressing a dominant negative (dn) form of the 
inhibitor of 
 
 
 
B
 
 
 
 under the control of an astrocyte-specific promoter (glial fibrillary acidic 
protein [GFAP]–dn mice) leads to a dramatic improvement in functional recovery 8 wk after 
contusive spinal cord injury (SCI). Histologically, GFAP mice exhibit reduced lesion volume 
and substantially increased white matter preservation. In parallel, they show reduced 
expression of proinflammatory chemokines and cytokines, such as CXCL10, CCL2, and 
transforming growth factor–
 
 
 
2, and of chondroitin sulfate proteoglycans participating in 
the formation of the glial scar. We conclude that selective inhibition of NF-
 
 
 
B signaling in 
astrocytes results in protective effects after SCI and propose the NF-
 
 
 
B pathway as a 
possible new target for the development of therapeutic strategies for the treatment of SCI.
 
In spinal cord injury (SCI) progression, the first
phase of damage, dependent on mechanical de-
struction of the nervous tissue, is followed by a
secondary phase caused by severe local distur-
bance of the blood supply and a massive release
of proinflammatory mediators and neurotoxins
from invading and resident cells (1). Although
inflammation is the physiological process by
which vascularized tissues respond to injury, an
overactivation of this process can lead to addi-
tional damage to the spinal cord, preventing
neural recovery and regeneration and, ulti-
mately, resulting in worsening of the clinical
outcome (2). A prominent source of inflamma-
tory mediators is astroglia, which, in response
to injury, undergoes a profound activation
known as reactive astrogliosis, whose biological
importance is still a matter of debate (3). Even
though reactive astrocytes release factors essen-
tial for neuronal survival and wound healing (4,
5), they are also responsible for the production
of molecules detrimental to functional recovery
and for creating an environment unfavorable to
nerve regeneration (6).
Many of the processes occurring in reactive
astrocytes as a consequence of central nervous
system (CNS) damage are regulated by NF-
 
 
 
B
(7). In brain injury and SCI models, NF-
 
 
 
B is
highly activated (8–11) and the expression of
NF-
 
 
 
B–dependent genes is up-regulated (12,
13), indicating a critical function of this factor
in CNS pathophysiology. NF-
 
 
 
B activation in
astrocytes induces both detrimental and protec-
tive effects on CNS recovery. As for the detri-
mental function, NF-
 
 
 
B activation promotes
the transition of astrocytes to a substrate non-
permissive to neurite outgrowth (14). Inhibi-
tion of NF-
 
 
 
B down-regulates the glial re-
sponse to excitotoxic brain injury, resulting in
neuroprotection (15). As for the protective
function, NF-
 
 
 
B activation in astrocytes leads
to the synthesis of neurotrophins (nerve growth
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factor and brain-derived neurotrophic factor) essential for
neuronal survival (16). After brain injury, NF-
 
 
 
B–dependent
expression of calbindin exerts a cytoprotective effect prevent-
ing astrocyte apoptosis (17). Collectively, these reports point
to a complex function of NF-
 
 
 
B in astroglial cells, whose bi-
ological importance still needs to be fully clarified.
To address the contribution of astroglial NF-
 
 
 
B to CNS
pathophysiology, we generated a transgenic (TG) mouse line
in which NF-
 
 
 
B was selectively inactivated in astrocytes by
targeting the overexpression of a dominant negative (dn)
form of the inhibitor of 
 
 
 
B
 
 
 
 (I
 
 
 
B
 
 
 
) to astrocytes by means
of the astrocyte-specific glial fibrillary acidic protein (GFAP)
promoter. Taking advantage of this model, we provide evi-
dence that inactivation of NF-
 
 
 
B in astrocytes has beneficial
implications in SCI that result in the reduction of lesion vol-
ume, increased white matter preservation, reduction in pro-
teoglycan expression, modulation of the inflammatory re-
sponse, and dramatically improved functional recovery after
contusive injury.
 
RESULTS
Generation and characterization of GFAP-I
 
 
 
B
 
 
 
-dn mice
 
Unlike whole animal knockouts of p65 and p50 that display
either lethal (p65) or severe (p50) immunological complica-
tions (18, 19), GFAP-I
 
 
 
B
 
 
 
-dn mice survive normally to
adulthood and do not exhibit any apparent abnormal sen-
sorimotor phenotype. Transgene expression, measured by
RT-PCR, was detected in the CNS (both brain and spinal
cord) and in the peripheral nervous system (sciatic nerve; Fig.
1 A). This latter finding is justified by the well-documented
expression of GFAP in nonmyelinating Schwann cells (20).
No ectopic expression was detected in the heart, lung, kid-
ney, liver, or spleen (Fig. 1 A). To functionally confirm the
ability of truncated I
 
 
 
B
 
 
 
 to prevent NF-
 
 
 
B activation, a se-
ries of electrophoretic mobility shift assays (EMSAs) was per-
formed on nuclear extracts from astrocytes isolated from WT
and GFAP-I
 
 
 
B
 
 
 
-dn mice (Fig. 1, B and C). WT astrocytes
stimulated with TNF-
 
 
 
 exhibited a strong induction of NF-
 
 
 
B DNA binding activity, whereas no induction was de-
tected in TG astrocytes (Fig. 1 B). To confirm the cell speci-
ficity of transgene expression, similar EMSA experiments
were performed on neurons from GFAP-I
 
 
 
B
 
 
 
-dn mice and
WT littermates (Fig. 1 C). As expected, when stimulated
with TNF-
 
 
 
, GFAP-I
 
 
 
B
 
 
 
-dn neurons showed an increase
in NF-
 
 
 
B DNA binding activity comparable to WT neu-
rons, demonstrating the complete functionality of the NF-
 
 
 
B
pathway in this cell type (Fig. 1 C). To identify the molecular
composition of the NF-
 
 
 
B dimers, supershift experiments
were performed on astrocyte cultures from WT mice (Fig. 1
D). Preincubation of extracts from TNF-
 
 
 
–treated cultures
with anti-p65 and -p50 antibodies induced a supershift or an
attenuation of the specific electrophoretic band, respectively,
identifying the p65–p50 dimer as the main NF-
 
 
 
B complex
recruited after TNF-
 
 
 
 treatment in our model.
To investigate possible phenotypic abnormalities result-
ing from the genetic manipulation, a series of behavioral tests
was conducted. Locomotor behavior in a novel environ-
ment was assessed with the open field and grid walk tests. In
both tasks, male and female GFAP-I
 
 
 
B
 
 
 
-dn mice performed
equally to their WT counterparts (Fig. S1, A and B, available
at http://www.jem.org/cgi/content/full/jem.20041918/DC1),
indicating the absence of gross locomotor deficits.
Sensorimotor function was further evaluated with the
following tests: vibrissae-elicited and visually elicited reflex-
ive placing of forelimbs, wire test, tactile/proprioceptive
hindlimb placing, grip strength, and balance beam assess-
ments. In all tests, both male and female GFAP-I
 
 
 
B
 
 
 
-dn
mice performed equally to WT mice (unpublished data). In
addition, WT and GFAP-I
 
 
 
B
 
 
 
-dn mice performed compa-
rably well in the visual cliff test, indicating the absence of vi-
Figure 1. Biochemical characterization of GFAP-I B -dn mice. 
(A) RT-PCR analysis of GFAP-I B -dn (I B -dn) expression in the brain 
(Br), spinal cord (SC), sciatic nerve (SN), heart (Ht), kidney (Kd), lung (Ln), 
liver (Lv), and spleen (Sp).  -Actin was amplified as a control. Samples lack-
ing RT ( RT) were amplified as controls for genomic DNA contamination. 
Genomic DNA from a TG animal and water were used as positive ( ) and 
negative ( ) controls for the PCR reaction, respectively. (B) Inhibition of 
NF- B DNA binding activity exclusively in astrocytes from GFAP-I B -dn 
(I B -dn) mice. Cultures were treated with TNF-  ( , 10 ng/ml for 30 min) 
or medium alone ( ). (C) Induction of NF- B DNA binding activity exclu-
sively in neurons from GFAP-I B -dn (I B -dn) mice. Cultures were treated 
with TNF-  ( , 10 ng/ml for 30 min) or medium alone ( ). (D) NF- B super-
shift in TNF- –stimulated WT astrocytes. Nuclear extracts from WT astro-
cytes, treated with TNF-  ( , 10 ng/ml for 30 min) or medium alone ( ) 
were preincubated with anti-p65 or -p50 antibodies. The supershifted p65–
p50 dimer is detected in the top left (ss). Binding specificity to the NF- B 
consensus sequence was demonstrated by displacement of the 32P-labeled 
NF- B oligonucleotide in the presence of 100-fold excess cold NF- B and 
by a lack of displacement in the presence of 100-fold excess cold AP-1. 
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sual acuity deficits (unpublished data). Finally, when tested
with the elevated plus maze and the light/dark transition
test, GFAP-I
 
 
 
B
 
 
 
-dn mice exhibited levels of anxiety similar
to WT littermates (unpublished data). Together, these data
indicate the absence of gross behavioral abnormalities related
to the expression of the transgene, validating our experimen-
tal model as suitable for CNS injury studies.
 
Inactivation of astroglial NF-
 
 
 
B has no effect on spinal cord 
architecture, neuronal number, or constitutive cell death
 
Standard cresyl violet histopathology and immunohistochem-
istry with the astrocyte-specific marker GFAP and neuron-
specific Nissl staining did not reveal any gross morphological
anomalies in the architecture of the naive spinal cord in
GFAP-I
 
 
 
B -dn mice (Fig. S2, A–D, available at http://
www.jem.org/cgi/content/full/jem.20041918/DC1). To
rule out any subtle abnormality undetectable by standard
qualitative histology, we stereologically counted the number
of neurons in naive WT and GFAP-I B -dn spinal cords
based on NeuN immunostaining. No difference was detected
between the two genotypes (neuronal number   SEM: WT,
370,479   12,948; GFAP, 377,895   20,308), suggesting
that inactivating NF- B in astrocytes does not lead to devel-
opmental anomalies in the neuronal population (Fig. S2 E).
Based on the well-documented implication of NF- B in
regulating both pro- and antiapoptotic mechanisms (21), we
further investigated whether GFAP-I B -dn mice displayed
a different pattern of cell death when compared with WT
mice. TdT-mediated dUTP-biotin nick-end labeling
(TUNEL) staining of the naive spinal cord revealed the ab-
sence of constitutive cell death (absence of TUNEL  cells)
in both WT and GFAP-I B -dn mice (Fig. S2 F), suggest-
ing that, at least in the spinal cord, astroglial NF- B is not a
critical regulator of apoptotic/necrotic programs under non-
pathologic conditions.
Activation of NF- B induced by SCI is prevented 
in GFAP-I B -dn mice
The role of astroglial NF- B in SCI pathophysiology was
evaluated in a model of moderate traumatic injury. We ini-
tially demonstrated that activation of NF- B occurred after
injury in WT mice (Fig. 2). NF- B activation was evaluated
by Western blot with an antibody that specifically recognizes
an epitope overlapping the nuclear localization signal of the
p65 subunit and, thus, selectively binds to the activated form
of p65 (p65*). Western blot analysis indicated increased NF-
 B activation as early as 1 h after SCI that persisted for up to
3 d. These results parallel our previous findings in a similar
contusion model in the rat (8). Activated p65 was detected as
a doublet of bands migrating at an apparent molecular mass
of 65 and 67 kD, respectively, with the heavier band possi-
bly representing a hyperphosphorylated form of p65. Indeed,
it has been reported that phosphorylation enhances the trans-
activation potential of p65, which is required for optimal
NF- B activation (22). Remarkably, SCI-induced NF- B
activation was almost completely prevented in GFAP-I B -
dn mice, where only a mild increase in activated p65 could
be detected at 1 and 3 d.
Inactivation of astroglial NF- B improves functional 
recovery after SCI
To assess whether the blockade of NF- B had any effect on
functional recovery after SCI, locomotor performance in the
open field was recorded weekly for up to 8 wk after injury
and scored with the Basso mouse scale (BMS; reference 23).
Compared with WT animals, GFAP-I B -dn mice exhib-
ited a dramatically improved functional recovery that was sta-
tistically significant as early as 1 d after injury (P   0.04; Fig. 3
A). Although recovery reached a plateau 2 wk after SCI in
WT mice (final BMS   SEM: 3.3   0.2), GFAP-I B -dn
mice showed a progressive gain of function until 6 wk after
injury (final BMS   SEM: 6.3   0.4). Histological analysis of
the injured cords 8 wk after SCI showed an apparently smaller
lesion in GFAP-I B -dn mice compared with WT (Fig. 3
B). Intense GFAP immunoreactivity was detected in both ge-
notypes around the lesion and in the surrounding white mat-
ter, indicating the formation of a glial scar. At the site of im-
pact, WT and TG mice displayed an equivalent degree of
damage (Fig. 3 B, cross sections). As typical of spinal cord le-
sions in mice, no cavitation or vacuolization of the tissue was
observed. Rather, the lesion area was filled with cells packed
at high density in both genotypes (Fig. 3 B, blue).
Inactivation of astroglial NF- B increases white matter 
sparing after SCI
To confirm the qualitative observations described, a stereo-
logical quantification of lesion volume and white matter
sparing was performed. Reduced lesion volume was ob-
served in GFAP-I B -dn mice (Fig. 3 C), although values
did not reach statistical significance. At the lesion epicenter
where tissue disruption was comparable in the two geno-
types, no difference was observed between WT and TG
mice in the total number of spared neurons (neuronal num-
ber     SEM: WT, 302,026    61,740; GFAP-I B -dn,
251,842   17,419). Importantly, stereological quantitation
of white matter on Luxol-stained serial sections (Fig. 3 D)
revealed more than double the amount of intact white mat-
ter (Fig. 3 D, contoured areas) in GFAP-I B -dn mice
compared with WT mice (mm3   SEM: 3.00   0.35 vs.
Figure 2. Time course of NF- B activation after SCI in WT and 
GFAP-I B -dn mice. NF- B activation was evaluated by Western blot 
analysis with an antibody that specifically recognizes the activated form 
of p65 (p65*). The arrowhead indicates p65* migrating at exactly 65 kD. 
20  g of proteins/sample were loaded, and blots were probed for  -actin 
as a control. A representative blot is shown (n   3). nv, naive.ROLE OF ASTROGLIAL NF- B IN SPINAL CORD INJURY | Brambilla et al. 148
1.44    0.34, respectively). Coimmunolabeling of tissues
with myelin basic protein (MBP; red) and neuronal class III
 -tubulin (TuJ1; green) demonstrated colocalization of in-
tact myelin with neuronal fibers bridging the lesion area in
GFAP-I B -dn mice (Fig. 4, C–F), indicating the presence
of preserved, and possibly functional, axons. In all the WT
sections tested, we were unable to colocalize MBP labeling
with TuJ1 within the lesion core (Fig. 4, A and B), indicat-
ing that axonal fibers running through the lesion area are
nonmyelinated and, thus, functionally compromised.
Figure 3. Behavioral and histological analysis of WT and GFAP-
I B -dn mice 8 wk after SCI. (A) Evaluation of hindlimb locomotor func-
tion. WT (n   12) and GFAP-I B -dn (I B -dn; n   12) mice were tested
1 d after SCI and weekly thereafter for 8 wk. Motor behavior was scored 
under blind conditions with the BMS. ^, P   0.04; *, P   0.001 versus WT, as 
determined by one-way ANOVA and the Tukey test. (B) GFAP labeling 
(green), fluorescent Nissl (red), and DAPI (blue) staining of spinal cord 
sections 8 wk after SCI. (C) Lesion volume assessment of the two genotypes 
(n   5). (right) A three-dimensional reconstruction of the lesion. (D) White 
matter sparing. Volume of myelinated white matter was measured in WT 
(n   5) and GFAP-I B -dn (n   5) mice on Luxol-stained sections. 
Contoured areas with darker Luxol staining delineate intact white matter. 
*, P   0.02, as determined by the Student’s t test. Morphometric analyses 
shown in C and D were conducted under blind conditions. Bars, 450  m.JEM VOL. 202, July 4, 2005 149
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Inhibition of astroglial NF- B results in reduced expression 
of neurocan and phosphacan after SCI
The expression of chondroitin sulfate proteoglycans
(CSPGs), which are essential constituents of the glial scar,
was evaluated by immunohistochemistry in WT and
GFAP-I B -dn mice 8 wk after injury. Both neurocan and
phosphacan were highly expressed within the lesion core
and in the white matter in WT mice (Fig. 5, A and C),
whereas greatly reduced immunoreactivity was observed in
TG mice (Fig. 5, B and D). In both genotypes, neurocan
and phosphacan were detected on GFAP  processes at the
lesion edge and in the white matter and were colocalized
with the microglia/macrophage marker OX-42 in the le-
sion core and in the white matter (unpublished data). To
begin elucidating the mechanisms at the basis of the de-
creased CSPG expression in TG mice, we examined the ex-
pression of TGF-  and decorin, molecules that are known
to be important regulators of such proteoglycans. We first
evaluated the expression of the three TGF-  isoforms by
RNase protection assay (RPA; Fig. 6 A). No differences
Figure 4. Immunostaining for MBP and TuJ1 in WT and GFAP-
I B -dn spinal cords 8 wk after SCI. WT (A and B) and GFAP-I B -dn 
(C and D) sections of the spinal cord were double labeled for MBP (red; B, 
D, and F) and TuJ1 (green; A, C, and E). White arrows in E and F show colo-
calization of MBP with TuJ1 in myelinated axons. Bars: (A–D) 180  m; 
(E and F) 50  m.ROLE OF ASTROGLIAL NF- B IN SPINAL CORD INJURY | Brambilla et al. 150
were detected for TGF- 1 and TGF- 3 in response to in-
jury and between WT and TG mice. TGF- 2 expression,
however, was significantly induced 6 h after SCI in WT
mice, and this effect was completely abrogated in GFAP-
I B -dn mice (P   0.05; Fig. 6 A). This result is particu-
larly important considering the role of TGF- 2 in stimulat-
ing the expression of CSPGs (24), and it correlates with the
reduced deposition of neurocan and phosphacan at later
times after injury (Fig. 5).
The expression of decorin, a small dermatan/GSPG that
is considered a natural antagonist to scar formation (25), was
quantified by real-time PCR (Fig. 6 B). No differences were
detected between WT and GFAP-I B -dn mice at 3 d and
1 wk after injury.
Inactivation of astroglial NF- B results in reduced 
expression of the chemokines CXCL10 and CCL2 after SCI
To investigate the molecular mechanisms relevant to the im-
proved functional outcome in GFAP-I B -dn mice, we
evaluated the expression of NF- B–dependent chemokines
known to be up-regulated after SCI as critical modulators of
the secondary injury response (26). mRNA levels of such
molecules were measured by RPA 6 h and 1 d after SCI.
Regulated on activation, normal T cell expressed and secreted
(RANTES) expression was up-regulated at 6 h and still ele-
vated at 1 d, with no noticeable difference between WT and
TG mice (Fig. 7 A). On the contrary, statistically significant
differences in the expression of CXCL10 (or IP10) and CCL2
(or MCP-1) were observed (P   0.05). CXCL10 expression
Figure 5. Neurocan and phosphacan immunohistochemistry 8 wk 
after SCI. WT (A and C) and GFAP-I B -dn (B and D) sections of the spi-
nal cord were double labeled for GFAP (red) and either neurocan (green; A 
and B) or phosphacan (green; C and D). Bars, 450  m.JEM VOL. 202, July 4, 2005 151
ARTICLE
was greatly increased in WT mice 1 d after SCI, and this ef-
fect was inhibited in GFAP-I B -dn mice (Fig. 7 A). Simi-
larly, SCI-induced CCL2 up-regulation was reduced in
GFAP-I B -dn mice compared with the WT (Fig. 7 A).
To further characterize the source of CXCL10 and
CCL2, we performed immunohistochemical studies 3 d after
SCI. CXCL10 (Fig. 7, green) was widely expressed
throughout the cord in the two genotypes and immunoreac-
tivity perfectly colocalized with GFAP (Fig. 7, B and C,
red), indicating that astrocytes represent the sole source of
the molecule at this phase of injury. Identical results were
obtained for CCL2 (unpublished data). These data, in com-
Figure 6. Expression of TGF-  and decorin in WT and GFAP-I B -dn 
mice after SCI. (A) Gene expression of TGF- 1, - 2, and - 3 6 h and 1 d 
after SCI was measured by RPA. Semiquantitative measurements were 
obtained by normalizing to GAPDH and L32. Results are expressed as the 
percentage of WT 6 h after SCI and represent the mean   SEM (n   4). 
*, P   0.05, as determined by one-way ANOVA and the Tukey test. (B) Decorin 
expression 3 d and 1 wk after SCI was measured by real-time RT-PCR and 
normalized to  -actin. Results are expressed as the percentage of WT 3 d 
after SCI and represent the mean   SEM (n   3). Samples were also ana-
lyzed by agarose gel electrophoresis.  , negative control for the PCR.
Figure 7. Chemokine expression in WT and GFAP-I B -dn mice 
after SCI. (A) Gene expression of RANTES, CXCL10, and CCL2 6 h and 1 d 
after SCI was measured by RPA. Semiquantitative measurements were 
obtained by normalizing to GADPDH and L32. Results are expressed as the 
percentage of WT 6 h after SCI and represent the mean   SEM (n   4). 
*, P   0.05 as determined by one-way ANOVA and the Tukey test. 
(B–D) Colocalization of CXCL10 immunostaining (green) with GFAP (red) 
in WT (B) and GFAP-IkBa-dn mice (C) 3 d after SCI. Bars, 20  m.ROLE OF ASTROGLIAL NF- B IN SPINAL CORD INJURY | Brambilla et al. 152
bination with the RPA data (Fig. 7 A), confirmed that NF-
 B acts as a direct regulator of CXCL10 and CCL2 expres-
sion. Furthermore, they provide evidence that inhibiting
NF- B in astrocytes effectively reduces the inflammatory re-
sponse in the early phase of injury because both CXCL10
and CCL2 are important chemotactic factors involved in the
development of inflammation by driving the infiltration of
leukocytes into the damaged spinal cord.
CXCL10 and CCL2 expression also temporally correlated
with the appearance of OX-42  monocytes/macrophages at
the lesion site in both WT (Fig. S3, A and B, available at
http://www.jem.org/cgi/content/full/jem.20041918/DC1) and
TG (Fig. S3, C and D) mice 3 d after SCI. OX-42  cells were
also very numerous outside of the lesion area and displayed the
typical stellate morphology of activated microglia (unpublished
data). Immunostaining for the T cell–specific marker CD3 re-
vealed the absence of T lymphocytes within the lesion 3 d after
injury (unpublished data), which is in agreement with a previ-
ous study indicating that, in the mouse, T cell infiltration oc-
curs at later times after injury (2 wk; reference 27).
Inactivation of astroglial NF- B results in increased 
expression of IL-6 after SCI
Finally, we evaluated the expression of two classic NF- B-
dependent cytokines, TNF-  and IL-6, because of their
documented proinflammatory function and up-regulation
after SCI (12, 28). TNF-  was up-regulated at comparable
levels in WT and GFAP-I B -dn mice (Fig. 8). Expression
peaked at 6 h and declined by 1 d. Conversely, at 6 h after
injury, IL-6 expression was significantly higher in GFAP-
I B -dn mice compared with the WT (P   0.05; Fig. 8).
This represents a rather unexpected result because NF- B is
a major transcriptional activator of IL-6 expression.
DISCUSSION
We provide evidence that the NF- B signaling pathway op-
erating in astrocytes is a major contributor to the pathological
events occurring after SCI. By generating a TG model in
which NF- B is specifically inactivated in astrocytes, we dem-
onstrated that, under nonpathologic conditions, astroglial NF-
 B is not a critical regulator of spinal cord development and
function. Indeed, TG mice display normal locomotor behav-
ior and retain complete integrity of spinal cord architecture.
Furthermore, we demonstrated the absence of constitutive cell
death in GFAP-I B -dn mice (similar to WT mice), indicat-
ing that, under physiologic conditions, the NF- B pathway
operating in astrocytes is not involved in the regulation of ap-
optotic mechanisms in the spinal cord. According to our data,
astrocytes do not require the presence of functional NF- B
for their viability under normal conditions, unlike hepatocytes
and B lymphocytes in which NF- B acts as a physiologic sur-
vival factor preventing apoptotic cell death (29, 30). In addi-
tion, we demonstrated that inhibition of NF- B in astrocytes
does not have any indirect effect on the viability of other CNS
cell types (e.g., neurons) under physiologic conditions.
After contusive SCI, NF- B is rapidly activated in WT
mice (Fig. 2), with a temporal profile that mirrors that ob-
served in the rat (8). In contrast, NF- B activation is almost
completely prevented in GFAP-I B -dn mice. This result
has two important implications. First, it is a further confir-
mation that the transgene is highly functional in blocking
NF- B. Second, at least at early times after injury, it suggests
that astrocytes are the major cell type in which the “bulk” of
NF- B activation occurs.
From a behavioral point of view, GFAP-I B -dn mice
exhibited, over time, a dramatic functional improvement
compared with WT mice. At the end of an 8-wk period of
post-injury testing, TG mice locomotor capability was sub-
stantially ameliorated with respect to WT, as indicated by an
approximately three-point increase in the BMS score. This
translated into the ability of GFAP-I B -dn mice to perform
coordinated movements and plantar stepping. WT mice, on
the other hand, not only lacked coordination, but were often
unable to support their weight when moving. Histologically,
GFAP-I B -dn mice exhibited a statistically significant in-
crease in white matter preservation. This likely accounts for
their improved functional outcome caused by a higher num-
ber of spared axons extending through the intact white matter,
the presence of which was demonstrated in double-labeling
experiments showing colocalization of MBP with the neu-
ronal-specific marker TuJ1 (Fig. 4). We also cannot exclude
the possibility that a certain degree of regeneration might oc-
cur in GFAP-I B -dn mice, allowing for reinnervation of
peripheral muscles and, consequently, better locomotion. In
support of this speculation, a recent study by de Freitas et al.
(14) demonstrated that the capacity of heat-stressed (reactive)
astrocytes to inhibit neurite growth is dependent on NF- B
activation. In our TG model, the nonpermissive properties of
astrocytes may be abrogated by the constitutive inactivation of
the NF- B pathway, resulting in an increased ability of dam-
aged neurons to regenerate their axons. To specifically test this
hypothesis, axonal tracing experiments are currently ongoing.
Morphological analysis of the injured spinal cords in WT mice
revealed the presence of a more elongated lesion than in
GFAP-I B -dn mice (Fig. 3, B and C), suggesting that astro-
glial NF- B may be involved in the spreading of the damage
to the areas surrounding the site of injury.
Figure 8. Expression of TNF-  and IL-6 in WT and GFAP-I B -dn 
mice after SCI. Gene expression of TNF-  and IL-6 6 h and 1 d after SCI 
was measured by RPA. Semiquantitative measurements were obtained by 
normalizing to GADPDH and L32. Results are expressed as the percentage 
of WT 6 h after SCI and represent the mean   SEM (n   4). *, P   0.05, as 
determined by one-way ANOVA and the Tukey test.JEM VOL. 202, July 4, 2005 153
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To investigate the molecular mechanisms at the basis of
the functional improvement in GFAP-I B -dn mice, we
evaluated the expression of molecules known to be secreted
by astrocytes and participate in the formation of the glial scar,
namely the CSPGs neurocan and phosphacan, at chronic
time points (8 wk after SCI). CSPGs represent a class of ex-
tracellular matrix molecules highly expressed within the glial
scar and inhibitory to axonal regeneration (31, 32). Strategies
aimed at degrading CSPGs attenuate their inhibitory activity
and promote functional recovery after injury (33, 34). In our
model of SCI, we demonstrated that expression of neurocan
and phosphacan is highly attenuated in GFAP-I B -dn mice
compared with the WT (Fig. 5). This may result in reduced
glial scarring and, therefore, establish a more favorable envi-
ronment to neuronal regeneration. In addition, our data indi-
cate that NF- B plays a role in inducing neurocan and phos-
phacan production in astrocytes. NF- B may accomplish this
function either by directly activating the transcription of the
two genes or by indirectly inducing the expression of mole-
cules responsible for proteoglycan synthesis. Among these
molecules, a possible candidate is TGF- , a potent fibrogenic
factor implicated in scar formation (35, 36), whose expression
is regulated by NF- B (37, 38). Within the TGF-  family,
TGF- 2 expression has been correlated with the deposition
of scar tissue after SCI (24). We demonstrate that early ex-
pression of TGF- 2 induced by SCI is significantly reduced
in GFAP-I B -dn mice (P   0.05; Fig. 6 A). This represents
an important finding and allows us to speculate that inhibi-
tion of astroglial NF- B, by blocking the production of
TGF- 2, may remove a prominent stimulating factor for the
synthesis of scar-forming CSPGs and, therefore, help explain
the recovery of function observed in TG mice. In addition,
because it has been recently demonstrated that decorin re-
duces the expression of neurocan and phosphacan and pro-
mote axon growth across SCIs (39), we quantified decorin
gene expression in search of a possible correlation with the
reduced CSPGs observed in GFAP-I B -dn mice. Expres-
sion of decorin, a small dermatan/CSPG acting as a natural
inhibitor to scar formation (25) by blocking the activity of
TGF-  (40) and by antagonizing the epidermal growth factor
receptor (41), did not change between WT and TG mice at
early times after SCI, suggesting that decorin does not partic-
ipate in the antifibrotic effect observed. This result also indi-
cates that NF- B does not play a role in the transcriptional
regulation of mouse decorin (at least under these experimen-
tal conditions), as it does for TGF- .
Another interesting finding is that early SCI-induced up-
regulation of CXCL10 and CCL2 is considerably reduced in
GFAP-I B -dn mice. Because both CXCL10 and CCL2
are involved in blood cell chemotaxis, a reduction in their
expression could translate into a reduced infiltration of leu-
kocytes into the lesion area and contribute to containing the
inflammatory response after injury. In support of this hy-
pothesis, recent studies demonstrated that antibody-medi-
ated neutralization of CXCL10 enhances tissue sparing, re-
duces T cell infiltration, and improves functional recovery
after SCI (42, 43). This evidence, combined with our results
indicating the expression of CXCL10 and CCL2 in astro-
cytes 3 d after injury (Fig. 7, B and C), suggests that astroglial
NF- B is an important factor in driving the production of
CXCL10 and CCL2 after SCI and that blocking this path-
way has a beneficial effect on the functional outcome. The
fact that GFAP-I B -dn mice display a reduced expression,
but not a complete abrogation, of these chemokines 1 d after
SCI indicates that CXCL10 and CCL2 are likely regulated
by other transcription factors in addition to NF- B. Further-
more, we cannot exclude the possibility that the induction
of CXCL10 and CCL2 detected in both genotypes at these
early times after injury is caused by the contribution of cell
types other than astrocytes, particularly endothelial cells,
which are known sources of CXCL10 and CCL2 (44–46).
Gene expression experiments produced rather unex-
pected results with respect to TNF-  and IL-6, genes that are
classically regulated by NF- B. First, no difference was de-
tected in TNF-  expression between WT and TG mice after
SCI. This suggests that the early production of TNF-  occurs
in cell types other than astrocytes, most likely neurons and
microglia. Second, after SCI, GFAP-I B -dn mice exhibited
an up-regulation of IL-6 expression considerably higher than
that of WT mice, indicating that astroglial NF- B is not only
not required for IL-6 expression at this early stage, but may
also even represent an inhibitory signal. As for the role of IL-6,
an increasing body of evidence has been accumulating on
IL-6 neuroprotective function in CNS injury (47) and against
glutamate excitotoxicity (48, 49). A recent study by Cafferty
et al. in IL-6 knockout mice (50) determined that IL-6 is re-
quired for conditioning injury-induced regeneration of dorsal
column axons after SCI. Based on these data, we can specu-
late that an increased IL-6 expression in GFAP-I B -dn
mice early after SCI may activate protective mechanisms
leading to increased neuronal survival and/or regeneration.
In conclusion, our results provide the first direct evidence
that NF- B–dependent processes initiated in astrocytes are re-
sponsible for the development of damage after SCI and that inhi-
bition of such processes by gene-targeted inactivation of astro-
glial NF- B leads to dramatic functional improvement after SCI.
This, in a field where very little pharmacological tools are avail-
able, identifies a potential new therapeutic target for the devel-
opment of treatments for SCI. Because NF- B is a ubiquitous
molecule essential for several vital functions, including inhibition
of apoptotic cell death (51), we are well aware that inactivating
NF- B could result in deleterious side effects. However, by lim-
iting the treatment within a relatively narrow window in the
early stages of injury when the “burst” of NF- B activation (and
therefore the escalation of the inflammatory response) occurs,
such effects are likely to be prevented or at least contained. Fur-
thermore, the feasibility and efficacy of treatments targeting the
inhibition of NF- B (i.e., proteasome inhibitors; references 52
and 53) have been documented in various animal models, and
several clinical trials with these molecules are now ongoing for
cancer and inflammation-based pathologies (i.e., ischemia-reper-
fusion injury, rheumatoid arthritis, and psoriasis). In this scenario,ROLE OF ASTROGLIAL NF- B IN SPINAL CORD INJURY | Brambilla et al. 154
our studies provide clinical evidence that such treatments could
potentially be applied to the treatment of SCI.
MATERIALS AND METHODS
Generation of GFAP-I B -dn mice
GFAP-I B -dn mice were generated at the Transgenic Core Facility of the
University of Miami. The original pGfa2Lac-1 plasmid containing a 2.2-kb 5 
flanking sequence of the human GFAP promoter (gfa2) upstream of the LacZ
gene and a segment of the mouse protamine-1 gene (mP1) as a polyadenylation
site was a gift of M. Brenner (University of Alabama-Birmingham, Birming-
ham, AL; reference 54). The cDNA encoding for a truncated form of the hu-
man I B  gene (I B -dn; amino acids 37–317), excised from the pCMV4-
I B -dn vector provided by D.W. Ballard (Vanderbilt University School of
Medicine, Nashville, TN; references 54 and 55), was cloned downstream of
the gfa2 promoter. The resulting GFAP-I B -dn-mP1 expression cassette was
gel purified, microinjected into 1-d-old C57BL/6   SJL embryos, and trans-
planted into pseudopregnant C57BL/6   SJL mice. Transgenic founders were
backcrossed to isogenicity (8–10 generations) onto WT C57BL/6 mice. All
mice used in our experiments were 2–4 mo old and were obtained by breed-
ing heterozygous GFAP-I B -dn males with WT females. WT littermates
from the same breeding group were used as controls. All animals were housed
in a 12-h light/dark cycle in a virus/antigen-free facility with controlled tem-
perature and humidity and were provided with water and food ad libitum.
Traumatic SCI
Surgeries were performed at the Animal and Surgical Core Facility of the
Miami Project to Cure Paralysis according to protocols approved by the In-
stitutional Animal Care and Use Committee of the University of Miami.
Contusion injury was induced with the Electromagnetic Spinal Cord Injury
Device (developed at Ohio State University) adapted to the mouse (56). In
brief, adult female mice (3–4 mo old, 20–24 g in weight) were laminecto-
mized between vertebrae T8 and T10 and lowered at a predetermined im-
pact force of 2,000 dynes (moderate injury). After surgery, animals were
housed separately and treated with topical antibiotics and subcutaneous
Ringer’s solution to prevent fluid loss. Manual bladder expression was per-
formed twice a day. 50–80 mg of prophylactic antibiotic gentocin was ad-
ministered daily to prevent urinary tract infections.
Assessment of functional recovery after SCI
Recovery of function after SCI was determined by scoring the locomotor
hindlimb performance in the open field with the BMS (23), a 0–9 rating sys-
tem based on a modification of the BBB scale (57) and specifically designed
for the mouse. Under blind conditions, a team of two investigators evaluated
the mice over a 4-min time period 1 d after SCI and weekly thereafter. Be-
fore surgery, animals were acclimated to the open field and to handling to
prevent fear and/or stress behaviors that could bias the locomotor assessment.
Histopathology and immunohistochemistry
For paraffin histopathology, animals were perfused with FAM (37% formalde-
hyde, acetic acid, and methanol, 1:1:8 by volume) fixative. Tissue segments
containing the lesion area (3 mm on each side of the lesion) were paraffin em-
bedded and cut into 15- m-thick sections. Sections were stained with cresyl
violet for general morphology and tissue architecture and Luxol fast blue for
myelinated white matter. Neurons were labeled with an antibody against the
specific marker NeuN (1:500; Chemicon) and visualized with 3-3 -diami-
nobenzidine staining using the Elite ABC kit (Vector Laboratories) according
to manufacturer’s instructions. For immunofluorescent staining, animals were
perfused with 4% paraformaldehyde in 0.1 M PBS. Tissues were cryopro-
tected in 0.1 M PBS   20% sucrose and cryostat cut into 15- m-thick sec-
tions. Sections were incubated overnight at 4 C with antibodies against
GFAP (1:1,000; DakoCytomation), OX-42 (1:100; Serotec), MBP (1:500;
Chemicon), TuJ1 (Covance), CXCL10, and CCL2 (both 1:500; R&D Sys-
tems), followed by secondary species-specific fluorescent antibodies (Alexa
Fluor 488 and 594, 1:500; Molecular Probes) for 1 h at room temperature.
Morphometric analysis
Neuronal cell count.  Neurons were identified by NeuN immunostain-
ing. Sets of 10 sections/animal were selected according to unbiased sam-
pling criteria (58), and the total number of neurons was stereologically
quantified with StereoInvestigator (MicroBrightField, Inc.).
Lesion volume.  Lesion volume was determined as previously described
(12). Sets of 10 cross sections were selected according to unbiased sampling
criteria (58) and were stained with cresyl violet, and the volume of damaged
tissue was measured on a three-dimensional reconstruction with Neurolu-
cida (MicroBrightField, Inc.).
White matter sparing.  Sets of serial cross sections were stained with
Luxol fast blue. Intact white matter was traced as previously described (59),
and the volume was calculated on a three-dimensional reconstruction with
Neurolucida (MicroBrightField, Inc.).
All morphometric analyses were performed by a single investigator un-
der blind conditions.
Primary astrocyte and neuronal cultures
Primary astrocytes were prepared according to the protocol described by
Bolego et al. (60), with minor modifications. In brief, the brains of 7-d-old
pups were dissected and placed in HBSS without Ca/Mg and supplemented
with 0.6% glucose. Tissue was incubated for 30 min at 37 C in 0.125%
trypsin   10  g/ml DNase I and triturated. Cells were collected, resuspended
in medium 199   100 IU/ml penicillin/streptomycin and 10% FBS, and
plated onto poly–L-lysine–coated dishes. 2 d before use, cells were switched
to a chemically defined serum-free medium consisting of 199   N2.
Primary cortical neurons were obtained with the following procedure.
Cortices of E15 embryos were dissected in L15 medium supplemented with
200 IU/ml penicillin/streptomycin. Tissues were incubated in 0.25%
trypsin/ethylenediaminetetraacetate for 5 min at 37 C. Cells were collected,
resuspended in Eagle’s basal medium   10% FBS, 2 mM glutamine, 100
IU/ml penicillin/streptomycin, 25 mM KCl, and plated onto poly–
L-lysine–coated dishes. 1 d before use, neurons were switched to a serum-
free medium consisting of Eagle’s basal medium   N2. All media and re-
agents for tissue cultures were obtained from GIBCO BRL.
Total RNA isolation and RT-PCR
Total RNA was extracted with TRIzol (Invitrogen) according to the man-
ufacturer’s instructions. 2  g RNA were reverse transcribed with 200
U/sample SuperScript II (Invitrogen) and 90 ng/sample of random hexa-
mers (Promega). The GFAP-I B -dn transgene was amplified from 0.1- g
aliquots of cDNA in a standard PCR buffer (50 mM KCl, 1.5 mM MgCl2,
and 10 mM Tris-HCl, pH 8.3) containing 10 pmol of forward GFAP (5 -
TTC ATA AAG CCC TCG CAT CC-3 ) and reverse I B  (5 -ACA
GCC AGC TCC CAG AAG TG-3 ) primers and 0.5 U/sample of Ampli-
Taq DNA polymerase (Applied Biosystems). Mouse  -actin was amplified
as a control for the PCR reaction. Samples lacking reverse transcriptase
were amplified as a control for genomic DNA contamination.
Real-time PCR
Real-time PCR was performed with the Rotor-Gene 3000 (Corbett Research)
on cDNA samples obtained as described in the Total RNA...RT-PCR section
using the intercalating dye SYBR green (Molecular Probes) in the presence of
primer pairs specific for either decorin (forward, 5 -ATT CGC ATC TCA
GAC ACC AAC ATA ACT-3 ; reverse, 5 -GAC TGC CAT TCT CCA
TAA CGG TGA T-3 ) or  -actin (forward, 5 -ATG GTG GGA ATG GGT
CAG A-3 ; reverse, 5 -CAC GCA GCT CAT TGT AGA AGG-3 )
EMSA
After treatments, cells were collected for whole cell extract (neurons) or nu-
clear extract (astrocytes) preparation. Whole cell extracts were obtained by
scraping cells in ice-cold lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1
mM ethylenediaminetetraacetate, and 1% Triton X-100, pH 7.5) supple-JEM VOL. 202, July 4, 2005 155
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mented with protease inhibitors (Complete; Roche). After incubation on ice
for 30 min, suspensions were spun at 21,000 g for 20 min and supernatants
(whole cell extracts) were collected. Nuclear extracts were prepared according
to Dignam et al. (61). EMSAs were performed as previously described (8).
RPA
RPA experiments were performed with the Multi-Probe Ribonuclease Pro-
tection Assay RiboQuant (BD Biosciences). Total RNA was isolated from
spinal cord segments consisting of 2 mm of tissue rostral and caudal to the le-
sion epicenter. Sham-operated (laminectomy alone) WT and GFAP-I B -
dn mice were used as controls. 2- g RNA aliquots from each sample were
hybridized to an  -32P-labeled multiprobe template set (mCK-2b and mCK-
3b mouse cytokine sets, 3.95   105 cpm/ l; mCK-5c mouse chemokine set,
3.6   105 cpm/ l) according to the manufacturer’s instructions. RNase-pro-
tected probes were resolved on 4.75% polyacrylamide gels and visualized by
autoradiography. Autoradiograms were quantified with Quantity One (Bio-
Rad Laboratories). Samples were normalized against L32 and GAPDH.
Western blot for activated p65
For the detection of activated p65 in spinal cord extracts, proteins were re-
solved by SDS-PAGE on 10% gels, transferred to nitrocellulose membranes,
and blocked overnight in 5% nonfat milk. Membranes were probed with an
antibody recognizing the activated form of p65 (1:1,000; Chemicon), fol-
lowed by horseradish peroxidase–conjugated secondary antibody. Proteins
were visualized with a chemiluminescent kit (ECL; GE Healthcare). Blots
were also probed for  -actin as a loading control.
Statistical analysis
Statistical analysis was performed with a one-way analysis of variance
(ANOVA) followed by the Tukey test for multiple comparisons. In the case
of single comparisons, the Student’s t test was applied. P   0.05 was consid-
ered statistically significant.
Online supplemental material
Fig. S1 shows the behavioral characterization of GFAP-I B -dn mice. Fig.
S2 depicts the histological analysis of naive WT and GFAP-I B -dn spinal
cords. Fig. S3 shows OX-42 immunostaining in WT and GFAP-I B -dn
mice 3 d after SCI. Additional protocols are provided as online materials
and methods. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20041918/DC1.
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